CompletedNCT00257972
Aripiprazole or placebo added to lithium or valproate for mania in bipolarity
About this title
Study of Aripiprazole in Patients With Bipolar I Disorder
Read the official source — NCT00257972This study evaluated the effectiveness of aripiprazole for people with bipolarity.
Medication studyAges 18+Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the effectiveness of aripiprazole for people with bipolarity.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 89 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateOctober 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 400
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, France, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT00257972
- Official title
Show the full official title
Efficacy of Aripiprazole in Combination With Valproate or Lithium in the Treatment of Mania in Patients With Bipolar I Disorder Partially Nonresponsive to Valproate or Lithium Monotherapy
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedLittle Rock, United States · Riverside, United States · Deerfield Beach, United States
88 more locations
- Jacksonville, United States
- Maitland, United States
- Hoffman Estates, United States
- Oak Brook, United States
- Newton, United States
- New York, United States
- Staten Island, United States
- Raleigh, United States
- Dayton, United States
- Media, United States
- Norristown, United States
- Philadelphia, United States
- Columbia, United States
- Memphis, United States
- Austin, United States
- Bellevue, United States
- Epping, Australia
- Rousse, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Brno-Bohunice, Czechia
- Hradec Králové, Czechia
- Opava, Czechia
- Prague, Czechia
- Pärnu, Estonia
- Tallinn, Estonia
- Tartu, Estonia
- Viljandi Maakond, Estonia
- Voru Maakond, Estonia
- Bordeaux, France
- Dole, France
- Grenoble, France
- Jonzac, France
- La Rochelle, France
- Limoges, France
- Marseille, France
- Nîmes, France
- Pessac, France
- Rennes, France
- Berlin, Germany
- Jena, Germany
- Magdeburg, Germany
- Meunchen, Germany
- Westersted, Germany
- Budapest, Hungary
- Gyula, Hungary
- Kecskemét, Hungary
- Nagykálló, Hungary
- Bassano del Grappa, Italy
- Cagliari, Italy
- Florence, Italy
- Pisa, Italy
- Roma, Italy
- Sassari, Italy
- Trieste, Italy
- Voghera -Pavia, Italy
- Retranchement, Netherlands
- Zaandam, Netherlands
- Choroszcz, Poland
- Kościan, Poland
- Krakow, Poland
- Poznan, Poland
- Torun, Poland
- Tuszyn, Poland
- Lisbon, Portugal
- Leningrad Region, Russia
- Moscow, Russia
- Saint Petersburg, Russia
- Smolensk, Russia
- Port Elizabeth, South Africa
- Westdene, South Africa
- Pretoria, South Africa
- Vereeniging, South Africa
- Welkom, South Africa
- Durban, South Africa
- Observatory, South Africa
- Barcelona, Spain
- Madrid, Spain
- Valencia, Spain
- Vitoria-Gasteiz, Spain
- Herisau, Switzerland
- Glasgow, United Kingdom
- London, United Kingdom
- Burnley, United Kingdom
- South Wales, United Kingdom
- Surbiton, United Kingdom
- Czechia
- Russia
Questions about this study
What did researchers investigate?
This study evaluated the effectiveness of aripiprazole for people with bipolarity.
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including aripiprazole.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
"A Randomized, Parallel Group, Open Trial Examining the Safety, Efficacy and Tolerability of Fast Titration, 800mg/day by day 4, of Quetiapine Fumarate Compared to Standard Titration, 400mg/day by ...
Aripiprazole added to divalproex for treatment-resistant bipolar depression